Bank of America Securities: Reiterates underperform rating on HUA HONG SEMI (01347), management cautiously optimistic about next year.
The bank believes that due to the healthier level of semiconductor inventory in China in the first half of the year, it is expected that the wafer prices of Huahong will moderately rise in the second half of the year. However, there is no expectation of an immediate shortage of chip supply, and the opportunity for further increase in wafer sales prices next year is unlikely.
Bank of America Securities released a research report stating that HUA HONG SEMI(01347) had sales of 635 million US dollars in the third quarter, a year-on-year increase of 21%, and a quarterly increase of 12%, in line with the bank's forecast of 636 million US dollars; gross profit margin was 13.5%, exceeding the guidance range of 10% to 12%. The bank reiterated its "underperform the market" rating on HUA HONG H shares with a target price of 59 Hong Kong dollars.
The bank mentioned that HUA HONG expects sales in the fourth quarter of this year to be between 650 million and 660 million US dollars, indicating a quarterly increase of 2% to 4%, with a gross profit margin of 12% to 14%, and is confident that the average selling price of semiconductor wafers will further improve in the fourth quarter. However, regarding price outlook for next year, the management is only cautiously optimistic, as intense competition suggests limited room for further increase in wafer prices, despite improvements in product portfolio and technological upgrades.
The bank believes that due to healthier semiconductor inventory levels in China in the first half of the year, wafer prices for the second half of the year for HUA HONG are expected to gradually increase, but there is no expectation of immediate chip supply shortage. The opportunity for further increase in wafer sales prices next year seems limited.
Related Articles

Non-executive director Guo Huaqing increased his holdings of CARSGEN-B (02171) by 70,000 shares, with a price of 14.8 Hong Kong dollars per share.
.png)
JP Morgan increased its holding of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by approximately 26,720 shares at a price of around HK$18.9 per share.

JP Morgan reduced its holdings in Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by approximately 117,500 shares at a price of around HK$18.96 per share.
Non-executive director Guo Huaqing increased his holdings of CARSGEN-B (02171) by 70,000 shares, with a price of 14.8 Hong Kong dollars per share.

JP Morgan increased its holding of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by approximately 26,720 shares at a price of around HK$18.9 per share.
.png)
JP Morgan reduced its holdings in Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by approximately 117,500 shares at a price of around HK$18.96 per share.

RECOMMEND

Short Positions on Xiaomi (01810.HK) Surge 53% in a Week as Memory Price Spike Weighs on Sentiment
07/11/2025

Privatization Wave in Hong Kong Stocks: Exiting Liquidity Traps to Enable Strategic Transformation
07/11/2025

Over 30 Foreign Firms Attend Roundtable as Ministry of Commerce Signals Multiple Policy Shifts
07/11/2025


